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Abstract
Background: We conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-
defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env from subtypes A, B and C,
given alone or as boost following a DNA plasmid vaccine expressing the same HIV-1 proteins plus Nef, in 114 healthy HIV-
uninfected African adults.
Methodology/Principal Findings: Volunteers were randomized to 4 groups receiving the rAd5 vaccine intramuscularly at
dosage levels of 1610
10 or 1610
11 particle units (PU) either alone or as boost following 3 injections of the DNA vaccine
given at 4 mg/dose intramuscularly by needle-free injection using BiojectorH 2000. Safety and immunogenicity were
evaluated for 12 months. Both vaccines were well-tolerated. Overall, 62% and 86% of vaccine recipients in the rAd5 alone
and DNA prime - rAd5 boost groups, respectively, responded to the HIV-1 proteins by an interferon-gamma (IFN-c) ELISPOT.
The frequency of immune responses was independent of rAd5 dosage levels. The highest frequency of responses after rAd5
alone was detected at 6 weeks; after DNA prime - rAd5 boost, at 6 months (end of study). At baseline, neutralizing
antibodies against Ad5 were present in 81% of volunteers; the distribution was similar across the 4 groups. Pre-existing
immunity to Ad5 did not appear to have a significant impact on reactogenicity or immune response rates to HIV antigens by
IFN-c ELISPOT. Binding antibodies against Env were detected in up to 100% recipients of DNA prime - rAd5 boost. One
volunteer acquired HIV infection after the study ended, two years after receipt of rAd5 alone.
Conclusions/Significance: The HIV-1 rAd5 vaccine, either alone or as a boost following HIV-1 DNA vaccine, was well-
tolerated and immunogenic in African adults. DNA priming increased the frequency and magnitude of cellular and humoral
immune responses, but there was no effect of rAd5 dosage on immunogenicity endpoints.
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Introduction
In a Phase IIb/III community-based clinical trial in Thailand,
prevention from HIV infection was demonstrated for the first time
with a combination of ALVAC-HIV (canarypox vectored HIV
vaccine) and AIDSVAX B/E (recombinant protein-based HIV
vaccine) [1]. Vaccine efficacy was modest and there was no effect
on viral load. Thus, the development of a safe and more efficacious
preventive HIV vaccine remains a high public health priority.
A recombinant multiclade adenovirus type 5 (rAd5) vector-
based vaccine expressing HIV-1 subtype B Gag and Pol and
subtypes A, B and C Env (VRC HIV-1 rAd5), and a recombinant
DNA vaccine encoding the same proteins plus subtype B Nef
(VRC HIV-1 DNA), developed by the Vaccine Research Center
(VRC) at the National Institute of Allergy and Infectious Diseases
(NIAID) of the National Institutes of Health (NIH), have been
evaluated previously either alone or in a DNA prime - rAd5 boost
combination in healthy, HIV-uninfected volunteers; both vaccines
were well-tolerated and immunogenic [2,3,4,5,6,7]. To further
develop these vaccines, three clinical studies were conducted
simultaneously: i) the V001 study - presented here - sponsored by
the International AIDS Vaccine Initiative (IAVI) in collaboration
with the Division of AIDS (DAIDS)/NIAID/NIH, conducted in
Kenya and Rwanda, ii) the HIV Vaccine Trials Network (HVTN)
204 study sponsored by DAIDS, NIAID, conducted in the US,
Latin America, the Caribbean and South Africa and iii) the US
Military HIV Research Program (USMHRP) sponsored RV172
study supported by DAIDS, NIAID, conducted in Kenya, Uganda
and Tanzania [8]. The three trials were randomized, double-
blind, placebo-controlled and tested the same vaccines in HIV-
seronegative volunteers. RV172 enrolled 324 volunteers and used
the same vaccination schedules as V001. HVTN 204 enrolled 480
volunteers and evaluated the DNA prime - rAd5 boost schedule
only. The objectives of the studies were to evaluate the safety and
immunogenicity of the two vaccines in preparation for future
Phase IIb and efficacy trials. After publication of the STEP study
results [9,10] in November 2007, plans for larger trials using rAd5-
vectored vaccines were suspended temporarily. The two vaccines
are currently being tested in a Phase II safety and effectiveness trial
in the US in HIV-uninfected, circumcised men who have sex with
men and who are negative for neutralizing antibodies against Ad5
at baseline. (HVTN 505; http://clinicaltrials.gov/ct2/show/
NCT00865566).
Participants
Healthy HIV-uninfected adults aged 18–50 years were recruited
at the Kenya AIDS Vaccine Initiative (KAVI), Nairobi, Kenya
and at Project San Francisco (PSF), Kigali, Rwanda. Volunteers
reported no increased risk for HIV (i.e., unprotected vaginal or
anal sex with known HIV infected person; sex in exchange for
money or drugs; a sexually transmitted infection within 6 months
before vaccination). They were willing to undergo HIV testing and
receive results. They agreed to use effective contraceptive methods
for the duration of their participation if sexually active and not to
become pregnant. Baseline serum neutralizing antibodies against
Ad5 were measured, but not used as an eligibility criterion. All
participants provided written informed consent.
Ethics Statement
This study was a double-blind, randomized, placebo-controlled
Phase I clinical trial (Table 1), approved by the appropriate local
and international Independent Ethics Committee (IEC) or Institu-
tional Review Board (IRB), and scientific and regulatory authorities
as follows: in Kenya [Kenyatta National Hospital Ethics and
Research Committee (KNHERC), the National Council of Science
and Technology (NCST) and the Institutional Biosafety Committee
(IBC)]; in Rwanda [The Rwanda National Ethics Committee, The
Ministry of Health and The Institutional Biosafety Committee]; and
in the USA (NIAID IRB and the Emory University IRB). The study
was conducted according to International Conference on Harmo-
nisation - Good Clinical Practice (ICH-GCP) and Good Clinical
Laboratory Practice (GCLP) [11].
Table 1. Number of Volunteers Enrolled, Vaccination Schedule, Sample Collection and Assessment Time Points.
Group (N/n)
a Vaccines/Dosage Group
b W0 W2 W4 W6 W8 W10 W12 W24 W28 W30 W36 W48
A (13/5) rAd5 10
10 S
c,d,e Q S
e S
c,d,e S
d S
d S
c,d.e
B (13/4) rAd5 10
11 S
c,d,e Q S
e S
c,d,e S
d S
e S
c,d,e
C (29/11) 3DNA + rAd5 10
10 S
c,d,e QQ Q S
d,e S
d S
c,d,e Q S
c,d,e S
d,e S
d S
c,d,e
D (29/10) 3DNA + rAd5 10
11 S
c,d,eQQ Q S
d,e S
d S
c,d,e Q S
c,d,e S
d,e S
d S
c,d,e
a(N/n) Number of vaccine recipients/number of placebo recipients per group.
bVaccines/Dosage Groups:
- rAd5: VRC HIV-1 rAd5 at 1610
10 or 1610
11 PU
- 3DNA: 3 doses of VRC HIV-1 DNA at 4 mg/dose given intramuscularly by needle-free injection using Biojector H 2000.
Qindicates vaccination visit.
S: Sample collection and assessment time points (S):
cSerum neutralizing antibodies against Ad5.
dVaccine-induced HIV-1 specific cellular immune responses.
eVaccine-induced HIV-1 specific humoral immune responses.
doi:10.1371/journal.pone.0012873.t001
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The study vaccines were designed and constructed at the
Vaccine Research Center (VRC), Bethesda, MD, USA and were
described previously [3,5].The recombinant, multiclade HIV-1
DNA vaccine (VRC-HIVDNA016-00-VP) is composed of six
individual, closed, circular plasmids expressing clade B HIV-1 gag,
pol, nef and clades A, B and C env. 50% of the mass is represented
by gag, pol, nef and the other 50% by EnvA, Env B and EnvC
(16.67% each). The recombinant, multiclade HIV-1 adenoviral
vector (VRC-HIVADV014-00-VP) is composed of four replica-
tion-defective, serotype 5 adenoviral vectors in a 3:1:1:1 ratio
encoding HIV-1 Clade B Gag-Pol polyprotein and HIV-1 Env
glycoproteins from clades A, B, and C. In the rAd5 vector, the
Gag-Pol genes are present as fusion protein.
The rAd5 vaccine was given intramuscularly by needle injection
at dosage levels of 1610
10 particle units (PU; low dosage, LD) or
1610
11 PU (high dosage, HD). The DNA vaccine was given at
4 mg/dose intramuscularly by needle-free injection (BiojectorH
2000) (Table 1). Phosphate buffered saline was used as placebo
for the DNA vaccine; final formulation buffer (VRC–DILU-
ENT013-DIL-VP) was used as placebo for the rAd5 vaccine.
Neither of the study vaccines can cause HIV infection.
Objectives
The primary objective of the V001 study was to evaluate the
safety and tolerability of a rAd5 vector expressing multiple HIV-1
proteins at two different dosage levels, given alone or as a boost
followingDNAplasmid vaccine inhealthyHIV-uninfected adultsin
East Africa. The secondary objective was to evaluate the humoral
and cellular immunogenicity of the vaccine at each dosage level.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Safety monitoring
Study participants were monitored by interim medical history,
and by physical and laboratory assessments. Local (pain,
tenderness, erythema, induration, edema, papule, blister/vesicle,
scab) and systemic signs and symptoms (headache, fever, chills,
malaise and/or fatigue, myalgia, arthralgia, nausea, vomiting)
were solicited for 3 days. Unsolicited adverse events (AEs) were
recorded throughout the study, graded for severity (Grade
1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=
potentially life threatening) and classified by MedDRA (Medical
Dictionary for Regulatory Activities). The AEs were assessed for
relationship to study vaccines. There were 5 categories of
relatedness: definitely, probably, possibly, probably not and not
related. All safety data were reviewed quarterly by an independent
Data and Safety Monitoring Board (DSMB). Protocol deviations
were monitored throughout the trial.
HIV testing
At screening, HIV testing was performed according to the
respective national algorithms. Only HIV-seronegative individuals
were enrolled. During the study, a protocol-specific algorithm was
followed, using two different HIV-1 ELISA tests selected from
Abbott Murex HIV Ag/Ab Combination Assay (Manufactured by
Murex Biotech Limited, United Kingdom), Vironostika Uni-Form
II Plus O (Manufactured by BioMerieux bv, Boxtel, The
Netherlands) or Adaltis Detect HIV v2 (ADALTIS Inc. Montreal,
Quebec Canada). If an ELISA test result was positive, a nucleic
acid test (HIV RNA PCR, Roche Amplicor Standard Assay V1.5
manufactured by Roche Diagnostics GmbH, Mannheim, Ger-
many) was performed to confirm or refute incident HIV infection
in the presence of vaccine-induced antibodies. During the study,
clinic staff was blinded to HIV test results. Volunteers who had a
positive HIV ELISA test results due to vaccine-induced antibodies
at the final study visit are being followed in a long-term follow up
study until serological test results return to negative.
Ad5 neutralizing antibody assay
Serum anti-Ad5 neutralizing titers were measured at baseline
and designated time points throughout the study (Table 1) using
previously described qualified assays [12,13]. Testing of baseline
sera for assessment of the impact of pre-existing Ad5 neutralizing
titers was done at Crucell Holland BV (Netherlands), and pre- and
post-vaccination Ad5 neutralizing titers were done at the NVITAL
Laboratory (Gaithersburg, MD). Briefly, heat inactivated, serially
diluted sera, rAd5 luciferase and 1610
4 A549 cells (human lung
carcinoma) were incubated in 96-well plates. The plates were
incubated for 24 hours and luciferase activity was quantitated in
lysed cell supernatants in a luminometer. The 90% inhibition
serum titer was determined to be the serum dilution that can be
interpolated to have 10% of the maximum luciferase activity, as
determined by the assay run without a serum sample. The cut-off
for a negative Ad5 titer was ,19 and ,12 for the Crucell and
NVITAL assays respectively. Study groups were stratified by
baseline Ad5 neutralizing titer, ,19, 19–200 and .200 (measured
by Crucell assay), which correspond approximately to the strata
used in the STEP trial analysis [9,10]. The proportion of
volunteers with any IFN-c ELISPOT responses after HIV-1
rAd5 alone was compared to HIV-1 DNA prime - rAd5 boost. For
immunogenicity assessments across multiple time points, the data
were stratified with a cut-off of ,12 using the NVITAL assay.
Humoral immunogenicity assays
Vaccine-induced HIV-1 specific humoral immune
response. An ELISA assay was used to delineate the antibody
response to each individual antigen encoded within the vaccine, as
previously described [3]. Testing was performed at the NVITAL
laboratory (Gaithersburg, MD). End-point titration of serum was
performed in 96-well Immulon2 (Dynex Technologies) plates coated
with preparations of purified recombinant proteins as described [3].
Titers were determined by sequential incubation of antigen with
antisera, followed by biotin-labeled anti-human IgG, IgA, or IgM,
and Streptavidin conjugated with horseradish peroxidase and TMB
(3, 59,5 , 5 9-tetra-methylbenzidine) substrate. Titer was calculated as
the most dilute serum concentration that gave an optical density
reading of .0.2 above background and reported as reciprocal
dilution.
HIV-1 neutralization. Neutralization was examined in
Groups A and B (rAd5 alone) at baseline, at 2 and 4 weeks post
vaccination and at final study visit (12 months after injection), and
in Groups C and D (DNA prime – rAd5 boost) at baseline, 2 weeks
after the 3
rd injection of the DNA vaccine, at week 24 immediately
prior to the rAd5 boost, 4 weeks and 6 weeks after the rAd5 boost,
and at final study visit (6 months after the boost). Neutralizing
activity was assessed against HIV isolates representing easy,
moderate and hard to neutralize HIV isolates from around the
world. The panel contained two primary isolates from each of the
following clades: A, B, C, D, circulating recombinant form
CRF01/AE and 2 lab adapted clade B isolates.
Neutralization was evaluated using a single-cycle recombinant
pseudotype virus assay by Monogram Biosciences, Inc. (San
Francisco, CA) as described previously [14]. Briefly, recombinant
Phase I HIV-Vaccine Study
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incubated for 1 h at 37uC with serial 4-fold dilutions of heat-
inactivated patient plasma samples. U87 cells that express CD4
plus CCR5 and CXCR4 were inoculated with the virus-plasma
dilutions and the virus infectivity was determined 3 days post
inoculation by measuring luciferase expression in the infected cells.
Neutralizing activity was reported as the percent inhibition of virus
infection at 4 dilutions as compared with controls containing no
test plasma. Virus pseudotyped with a murine leukemia virus
(MLV) env was used as a control for non-specific effects in the
assay. The cut-off for positivity was defined as greater than 1.7X
the MLV control and over 50% inhibition.
Cellular immunogenicity assays
IFN-c ELISPOT assay. Vaccine-induced HIV-1 specific T
cell responses were assessed at time points shown in Table 1 using
a validated IFN-c ELISPOT assay described previously
[15,16,17]. At KAVI, fresh peripheral blood mononuclear cells
(PBMC) were analyzed, whereas the IAVI Human Immunology
Laboratory analyzed previously frozen PBMC from KAVI and
PSF. Viable PBMC counted by Vi-Cell XR counter (Beckman
Coulter, UK) were plated at 2610
5 per well and stimulated in
quadruplicate overnight with vaccine-matched 15-mer peptides
overlapping by 11 aminoacids (aa), applied in pools of 100–200
peptides depending upon the protein, and at a final concentration
of 1.5–2 mg/mL. Peptide pools matching the vaccine were
supplied by the VRC; one pool each for EnvA, EnvB, Gag and
Nef and 2 pools for Pol. Responses to the EnvC pool were not
assessed due to high background responses observed in baseline
and placebo samples. A peptide pool consisting of 32 Influenza
(Flu), Epstein Barr Virus (EBV) and Cytomegalovirus (CMV)
peptides and PHA were used as controls [18,19]. Definition of a
positive response: 1) Spot Forming Cells per million (SFC/10
6)
PBMC more than 4 times the mean background SFC count and
greater than 38–68 SFC/10
6 cells (depending upon the peptide
pool) above the background. The cut-off was determined by the
level of non-specific response observed from at least 180 samples
from unvaccinated individuals. The cut-offs for EnvA, EnvB, Gag,
Nef and Pol pools 1 and 2 were 40, 51, 54, 68, 51 and 38,
respectively; 2) coefficient of variation across the replicate wells
,70%; 3) background: ,55 SFC/10
6 PBMC. A vaccine recipient
with a positive response to at least one pool is defined as a
responder.
Intracellular cytokine staining (ICS). ICS was measured
in 7 volunteers each of Groups C and D, and in 6 placebo
recipients at only three visits; baseline, 2 weeks post DNA and 4
weeks post rAd5. PBMC were shipped to NVITAL for testing.
The method used to detect CD4 and CD8 T cell responsiveness by
secretion of Interleukin-2 (IL-2) and/or IFN-c to HIV peptides via
ICS was based upon previously published methods [5]. Optimized
concentrations of peptide pools (the same peptide pools used for
the IFN-c ELISPOT assay, aside from EnvC, which was used in
the ICS but not ELISPOT assays) and antibodies to CD28 and
CD49D were added to a final total volume of 200 mL/well with a
total of 5.0610
5–1.0610
6 viable cells/well. The plates were
incubated for 6 hours in the presence of Brefeldin A. Following
cell permeabilization, the cells were stained with optimized
antibody concentrations for twenty minutes on ice. Antibodies of
4 colors were used to determine CD4 and CD8 T cell responses to
HIV antigens including: CD3 (APC conjugated), CD4 (PerCP
conjugated), CD8 (FITC conjugated), and a combination of
antibodies to IL-2, and IFN-c (both PE conjugated). Cells were
analyzed with an LSRII flow cytometer (Becton Dickinson, San
Diego, CA), and data analyzed with FlowJo software (Tree Star,
Inc., San Carlos, CA). Analysis determined the percent of CD4
and CD8 populations with intracellular cytokine expression at
levels above the background expression (anti-CD28/49D
stimulation only). The definition of a positive ICS response for
all peptide pools (CD4 and CD8) was 0.045%, except CD8 EnvC
(0.07%) and CD8 GagB (0.058%).
Viral inhibition assay (VIA). VIA was performed as
described elsewhere [20,21]. Briefly, PBMC were thawed,
divided into two aliquots and expanded for 7 days with bi-
specific CD3/CD8 or CD3/CD4 antibodies and IL-2 to generate
target CD4 and effector CD8 T cells respectively, resulting in
expansion and enrichment (.90% of the CD3 T cells in the
culture) of the required CD4 or CD8 T cell population. Separate
cultures were established containing target CD4 T cells alone
infected with either vaccine-matched or mis-matched HIV-1
isolates at an MOI of 0.01, and virus-infected target cells co-
cultured with autologous CD8 effector T cells from the baseline
pre-vaccination blood draw or from each post vaccination time
point to be assessed. To limit variation due to effects of the vaccine
regimen on the CD4 target cells, a single population of target CD4
cells was generated for each individual; where available this cell
population was generated from the baseline, pre-vaccination
sample. Every 3–4 days, culture supernatant was removed and
replaced with fresh media, and assessed for p24 content using a
commercially available ELISA (Perkin Elmer, UK). CD8 T cell-
mediated inhibition was expressed as log10 reduction in p24
content of day 13 CD8 and CD4 T cell co-cultures compared with
CD4 T cells alone. Viruses used for assessment of inhibition were
obtained from the National Institutes of Health AIDS Reference
and Reagent Program (Gaithersburg, MD) and included the lab-
adapted CXCR4-tropic clade B HIV-1-IIIB used as a reference
strain with pre-defined criteria for positivity (.1.13 log10 units of
inhibition) [21]. The primary isolates HIV-1-96ZM651 (clade C/
R5-tropic) and HIV-1-98IN017 (C/X4) were also assessed.
Sample size and Pause rules
The initial design called for 12 vaccine and 4 placebo recipients
in each of the study arms (a total of 64 volunteers). The study was
designed so that if there were no serious adverse events (SAE)
related to the vaccine in 48 volunteers, the upper bound of 95%
confidence interval was 0.06 for the probability that an SAE
related to vaccine could have occurred. Following review of initial
safety data of the candidate vaccines, Groups C and D were
increased to 27 vaccine and 9 placebo recipients to better inform
potential subsequent larger phase II studies. Thus, 104 volunteers
were planned to provide enhanced precision of the observed point
estimates of safety, tolerability and immunogenicity in volunteers
who received the VRC DNA prime - rAd5 boost regimen. An
over-enrollment of up to 10% was allowed, resulting in 114
volunteers overall.
The study stopping rules were to go into effect if there were one
or more grade 4 adverse events that were judged as probably or
definitely related to the study vaccine by the site clinician. If a
grade 4 adverse event occurred that was possibly related to the
study vaccine or a grade 3 adverse event was judged as definitely,
probably or possibly related to the vaccine, the independent
DSMB would be informed immediately and discuss whether or
not the study should pause until more information could be
collected.
Interim analyses
Annual interim analyses were performed. Blinded summary
tables and listings of adverse events, including solicited reacto-
genicity events, were presented to an independent DSMB.
Phase I HIV-Vaccine Study
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The randomization schedule was prepared by the statisticians at
the Data Coordinating Center, The EMMES Corporation. The
randomization list was sent to the site pharmacist of record for
dispensing of vaccine and placebo in a double-blind fashion. Study
site staff, volunteers, and laboratories remained blinded with
respect to the allocation of placebo or vaccine.
Statistical methods
Comparisons of reactogenicity and adverse events were made
by assigning scores of 0, 1, 2 and 3 to severities of none, mild,
moderate and severe. The Wilcoxon Rank sum test was used to
compare 2 groups; the Kruskal-Wallis test was used to compare
more than 2 groups. Fisher’s exact test was used for 262 tables.
These comparisons were based on the maximum severity per
volunteer. Immunogenicity results were tested using Fisher’s exact
test (2 groups) or the Kruskal-Wallis test. All tests are 2-tailed;
statistical significance is defined as a p-value of ,0.05. Analyses
were performed using SAS version 9.2, Cary, NC.
Results
Participant flow and Recruitment
As shown in Figure 1, 302 individuals were screened, of whom 114
volunteers (71 males, 43 females) were enrolled between November
2005 and May 2006. Table 2 shows the demographics by group
assignment. Ninety-four percent of all volunteers completed the
assigned administrations. No discontinuation was due to vaccine-
related adverse events. Follow-up was completed in April 2007.
Figure 1. CONSORT Flow Diagram. Number of individuals assessed for eligibility, enrolled and randomized to study vaccine(s) and respective
placebo, followed-up and analyzed.
doi:10.1371/journal.pone.0012873.g001
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There were 59 minor protocol deviations, mainly procedural
errors or study visits occurring outside the specified window period.
There was one violation of an exclusion criterion: a volunteer,
enrolled and randomized to Group C, received one injection of
study vaccine prior to availability of the result of hepatitis B surface
antigen (HbsAg), which was positive. Further vaccinations were
discontinued. Individual unblinding at study end revealed that this
volunteer was a placebo recipient. The interpretation of the data
presented here is not affected by the protocol deviations.
Vaccine Safety
Solicited events. Figure 2a shows local and systemic reacto-
genicity to the individual vaccines and the respective placebo during
the 3 days post-vaccination. Figure 2b shows local and systemic
reactogenicity following rAd5 alone and rAd5 boost by rAd5 dosage.
Local Reactogenicity. Local reactions (pain, tenderness and
vaccination site reactions/lesions) were reported by 92%, 85% and
100% of volunteers following rAd5 alone, rAd5 boost and DNA
injections (all 3 combined), respectively, and by 44%, 45% and
86% following the respective placebo injections. The most
common local reactions were mild (reported by 55.3% of all
volunteers), followed by moderate (33.3%) and severe (2.6%). Two
volunteers reported severe tenderness upon touch after the 1
st and
2
nd DNA vaccinations, respectively; a third volunteer reported
severe pain and tenderness after the rAd5 boost. Two volunteers
had moderate induration after the 1
st DNA vaccination, and two
had moderate edema after DNA placebo and rA5 boost,
respectively. There were no other moderate or greater local
reactions. No papules, blisters/vesicles or scabs were observed.
Overall, the maximum severity per volunteer was significantly
greater after rAd5 than after the corresponding placebo (p=0.006
and p,0.001 in Groups A and B and Groups C and D,
respectively). However, there was no significant difference between
DNA and corresponding placebo (p=0.137). The maximum
severity per volunteer over all local reactions was not associated
with dosage (p=0.301 and p=0.111 in Groups A and B and
Groups C and D, respectively), and there was no significant
difference between rAd5 alone or rAd5 boost (p=0.716).
Systemic signs and symptoms. Systemic reactions were
reported by 69%, 72% and 91% of volunteers following rAd5
alone, rAd5 boost and DNA injections (all 3 combined),
respectively, and by 78%, 55% and 81% following the
respective placebo injections. The most common systemic
reactions were mild (reported by 49.1% of all volunteers),
followed by moderate (25.4%) and severe (9.6%). Headache,
malaise and/or fatigue were most commonly reported. Eleven
vaccine recipients experienced severe events, lasting no more than
1–2 days. One volunteer reported severe headache, one severe
malaise following the first DNA injection and 9 volunteers (2 from
Group C, 7 from Group D) reported severe reactions following
rAd5 boost: headache (n=2); malaise (n=1); myalgia (n=1);
elevated temperature (n=2); arthralgia + malaise (n=1); malaise +
headache (n=1); and malaise + myalgia + headache + arthralgia
(n=1). No severe or greater systemic symptoms were reported
after rAd5 alone or in placebo recipients. No nausea or vomiting
was reported.
Overall, the maximum severity per volunteer was not
significantly different between rAd5 alone and placebo in Groups
A and B (p=0.566). However, in Groups C and D combined, the
maximum severity was higher in the vaccines than the placebo
group (p=0.036 and p=0.028 after any DNA injections and the
rAd5 boost, respectively).
Comparing the two dosage levels of rAd5, the maximum
severity per volunteer over all systemic reactions was not
associated with dosage (p=0.092 and p=0.126 after rAd5 alone
{Groups A versus B} and rAd5 boost {Group C versus D},
respectively); nor was there a significant difference between rAd5
alone (Groups A and B combined) or rAd5 boost (groups C and D
combined) (p=0.444). If the LD groups (A and C) are combined
and the HD groups (B and D) are combined, then the maximum
systemic reaction per volunteer post rAd5 is significantly higher
(p=0.025) in the HD group than in the LD group (41% versus
21%, respectively, were moderate or severe).
Reactogenicity by Ad5 neutralizing antibody titer at
baseline. The severity of local reactions tended to be highest in
subjects with baseline Ad5 neutralizing antibody titers to Ad5,19,
lower in those with titers .200, and lowest in volunteers with titers
between 19–200,butthedifferenceswerenotstatisticallysignificant.
Table 2. Demographics, by Group Assignment.
Category Placebo Recipients Vaccine Recipients
Group A/B
a N=9 Group C/D
b N=21 Overall N=30 Group A/B
a N=26 Group C/D
b N=58 Overall N=84
Gender
Male 6 (66.7%) 15 (71.4%) 21 (70.0%) 19 (73.1%) 31 (53.4%) 50 (59.5%)
Female 3 (33.3%) 6 (28.6%)
c 9 (30.0%) 7 (26.9%) 27 (46.6%)
c 34 (40.5%)
Age (yrs)
Mean 28.5 28.4 28.4 27.5 26.3 26.7
Range 20.3–44.6 19.7–39.0 19.7–44.6 19.5–48.8 18.3–37.8 18.3–48.8
Ad5 titers
# Non-Missing 7 21 28 26 57 83
Geometric Mean 489 338 370 341 288 303
Range 113–1819 16–3255 16–3255 16–4679 16–5000 16–5000
Completed Vaccination 9/9 (100%) 20/21 (95%) 29/30 (97%) 26/26 (100%) 53/58 (91%) 79/84 (94%)
aGroups A/B: rAd5 or Placebo alone.
bGroups C/D: DNA prime - rAd5 boost or Placebo - Placebo.
cIn Groups C/D, the number of vaccinated women is not statistically different from female placebo recipients.
doi:10.1371/journal.pone.0012873.t002
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signs and symptoms. (Figures S1 and S2).
Unsolicited adverse events. During the 12-month observa-
tion period, 777 unsolicited AEs were reported, of which 344
occurred within 28 days after any injection. Table 3 shows AEs
by severity and dosage group. 271/344 (79%) were graded as mild,
66 (19%) as moderate and 7 (2%) as severe. Overall, there were no
differences in the incidence or severity of unsolicited AEs, i.e.,
between rAd5 and placebo, rAd5 low and rAd5 high dosage, or
rAd5 alone and rAd5 boost, whether within 28 days or at any
time. Of 266 AEs occurring in vaccine recipients within 28 days
after vaccination, 42 (15.8%) were judged possibly or probably
related to study vaccines. The most frequent of these were
laboratory abnormalities (see next section) and influenza-like
syndromes. Similarly, of 78 AEs occurring in placebo recipients
within 28 days after administration, 15 (19.2%) were judged
related to study products before unblinding. These included
neutropenia, leucopenia, urticarial rash and influenza-like
syndrome. No epidemiological data are available on whether or
not influenza virus was circulating in the community at the time
these adverse events occurred. No blood samples were taken at the
time of events that were compatible with adenoviral infections to
look for serological evidence of infection with Ad5. Six events of
urticarial rash were reported in 5 volunteers at PSF; all resolved
spontaneously. Two events were moderate, one occurring 10 days
after the 1
st DNA and the other 71 days after the rAd5 boost. Two
events were mild, one occurring 48 days after the 3
rd DNA and the
other 276 days after rAd5 alone. The remaining 2 events were
mild and occurred in the same placebo volunteer (5 days after the
1
st DNA and on the day of the 3
rd DNA). All these events were
described as typical urticarial rashes. Furthermore, in vaccine
recipients the intervals between occurrence and the most recent
vaccination did not clinically support ‘‘immediate hypersensitivity
reaction’’ as a diagnosis. None of the rashes was accompanied by
other allergic reactions, nor were any vaccinations discontinued as
a result.
Laboratory abnormalities. Laboratory abnormalities were
mostly mild, with neutropenia (absolute counts) being the most
frequent. Moderate neutropenia (750 to ,1000 cells/mL) occurred
in 6 (7.1%) of the 84 vaccine recipients and 3 (10%) of 30 placebo
recipients. One severe (grade 3) neutropenia (740 cells/mL) was
detected 2 weeks after the 2
nd DNA injection, and one grade 4
neutropenia (450 cells/mL) was detected in an asymptomatic
volunteer 11 months after rAd5 alone. Two volunteers had a
moderate decrease of hemoglobin (6 months after the 1
st DNA
placebo and 3 months after rAd5 boost). There were 2 isolated,
moderate ALT elevations, at 6 months after rAd5 alone and 3
months after rAd5 boost. There were no other moderate or
greater laboratory abnormalities.
Serious Adverse Events. During the study, 6 serious adverse
events (SAEs) occurred in 6 vaccine recipients. These events were
cesarean section, complete abortion, phlebitis, discal hernia, pelvic
inflammatory disease, and fracture of the middle finger. None of
these events was considered related to study product.
Pregnancies. Three women became pregnant during the
study. One had completed her vaccination regimen before getting
pregnant and delivered a healthy baby. One woman, who had no
history of spontaneous abortion, was found to be pregnant 4 weeks
after the 1
st DNA injection and had a complete spontaneous
abortion one month later. The third woman delivered a term male
child by cesarean section due to cephalo-pelvic disproportion 41
weeks after the 3
rd DNA injection. No abnormalities were detected
either at birth or at 14 weeks of age. However, at the age of 12
months the child was found to have a congenital malformation (a
large arachnoidal cyst with agenesis of corpus callosum and a
parieto-occipital calvarial defect) and underwent endoscopic
fenestration and is now reaching age-appropriate developmental
milestones. The abnormality was assessed as probably not related
to study vaccine and was defined as ‘‘a potential relationship
between study agent and the adverse event could exist (i.e., the
possibility cannot be excluded), but the adverse event is most likely
explained by causes other than the study agent’’.
Figure 2. Solicited Local and Systemic Events. Figure 2a; Local reactogenicity and systemic signs and symptoms collected over 3 days post
vaccination. Maximum severity of local reactions was significantly greater after rAd5 than after placebo (p=0.006 and p,0.001 for rAd5 alone and rAd5
boost, respectively). For systemic signs and symptoms, the severity was significantly greater after DNA (p=0.036) and after rAd5 boost (p=0.028), than
after the corresponding placebo. Figure 2b; Local reactogenicity and systemic events post rAd5 by dosage. Combining low dosage (LD) groups and high
dosage (HD) groups, the maximum systemic reaction per volunteer post rAd5 was significantly higher (p=0.025) in the HD group than in the LD group
(41% versus 21%, respectively, were moderate or severe). Mild: open bars; Moderate: cross-hatched bars; and Severe: dark bars.
doi:10.1371/journal.pone.0012873.g002
Table 3. Number of Unsolicited Adverse Events within 28 Days Post Any Vaccination, by Severity and Group.
Group Treatment Grade 1 Mild Grade 2 Moderate Grade 3 Severe Total AEs
rAd5 Alone Low Dosage 12 (80.0%) 3 (20.0%) 0 (0.0%) 15
High Dosage 9 (90.0%) 1 (10.0%) 0 (0.0%) 10
Any Dose 21 (84.0%) 4 (16.0%) 0 (0.0%) 25
Placebo 8 (57.1%) 6 (42.9%) 0 (0.0%) 14
3DNA* Vaccine 143 (75.7%) 41 (21.7%) 5 (2.6%) 189
Placebo 45 (88.2%) 6 (11.8%) 0 (0.0%) 51
rAd5 Boost Low Dosage 22 (91.7%) 2 (8.3%) 0 (0.0%) 24
High Dosage 22 (78.6%) 5 (17.9%) 1 (3.6%) 28
Any Dose 44 (84.6%) 7 (13.5%) 1 (1.9%) 52
Placebo 10 (76.9%) 2 (15.4%) 1 (7.7%) 13
*AEs occurring within 28 days of any DNA or placebo injection (given at W 0, 4 and 8) combined.
doi:10.1371/journal.pone.0012873.t003
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infection during study follow up. One Group A volunteer acquired
HIV about 2 years after receipt of rAd5 alone, i.e., one year after
final study visit. At the time of diagnosis – six weeks after the
estimated date of infection - the viral load was 929 HIV RNA
copies/mL (2.97 logs). The baseline Ad5 neutralizing antibody
titer was 830. This volunteer is currently being followed in a long-
term follow up study specifically designed for HIV vaccine
recipients from any IAVI - sponsored clinical trial who acquire
HIV any time during or up to 2 years after the end of a study.
Vaccine Immunogenicity
IFN-c ELISPOT responses. The magnitude, response rate
and breadth of HIV-1 specific T-cell responses in each group and
the possible impact of pre-existing Ad5 antibodies on these
responses were assessed using an IFN-c ELISPOT assay.
Immune responses after rAd5 alone (Groups A
and B). Six weeks after administration of rAd5 1610
10 and
rAd5 1610
11, 6/13 (46%) and 7/13 (54%) volunteers, respectively,
had one or more positive responses by IFN-c ELISPOT to any pool
(Table 4). There were no responders among the placebo recipients.
Theresponserate invaccinerecipientswassimilarinthe twodosage
groups (2-sided Fisher’s exact test p-value.0.9), and significantly
higher than in placebo recipients (1-sided Fisher’s exact test p-
value,0.001). At the 48-week time point (final study visit) there
were 4/13 (31%) and 5/13 (38%) responders in Groups A and B,
respectively, all but one of whom were also positive at 6 weeks.
Immune responses after DNA prime – rAd5 boost
(Groups C and D). At 4 weeks after the 3
rd dose of DNA,
and prior to the rAd5 boost, 42% of vaccine recipients from both
groups combined had one or more positive responses (Table 4).
After the rAd5 boost, 72% and 69% of vaccine recipients had
positive responses at 6 weeks, and 81% and 80% had positive
responses at 6 months in Groups C and D respectively. Neither of
these differences was statistically significant. The highest frequency
of immune responses was observed at 24 weeks post rAd5 boost,
which was the final follow up study visit. In both groups C and D
the same number of volunteers, 25/29 (86%), had at least one
positive response at one or more visits after the initial vaccination.
Of the 36 volunteers with positive responses 6 weeks after the rAd5
boost, 33 (92%) were still positive at week 24, with responses to
EnvA and EnvB being the most persistent (24/29 and 21/24,
respectively, in the low and high dosage groups).
Response rates to rAd5 alone compared to DNA prime -
rAd5 boost. Figure 3 and Table 4 show that at 6 weeks post-
vaccination with rAd5, there was no significant difference in the
overall response rates between Groups A and B and Groups C and
D (50% versus 71%,p=0.0862). At the final study visit, which
occurred 48 weeks after rAd5 alone and 24 weeks after rAd5
boost, the prime-boost group had a much higher response rates for
IFN-c ELISPOT (35% versus 81%, p,0.001, Fisher’s exact 2-
tailed: 9/26 versus 42/52). The proportions of volunteers with
positive ELISPOT responses at 12 and 24 weeks post rAd5 boost
are higher than at 36 and 48 weeks after rAd5 alone. However, it
is unknown whether the high proportions in Groups C and D were
maintained up to 36 and 48 weeks, or whether the proportions in
Groups A and B at weeks 12 and 24 were higher than at week 36,
since no blood samples were taken at those time points in the
respective groups.
Magnitude of responses. The median (range) background-
subtracted number of SFC per 10
6 PBMC from responders 6
weeks after vaccination with rAd5 alone is 85 (52–297) for the low
and 78 (39–230) for the high dosage groups, respectively.
Similarly, 6 weeks after the rAd5 boost the median (range) SFC
counts are 91 (45–1420) and 105 (41–1707) per 10
6 PBMC,
respectively (see also below). The overall differences between
dosage groups after rAd5 alone or rAd5 boost were not statistically
significant. However, at each visit, the average magnitude of
positive responses per volunteer after the rAd5 boost was
statistically significantly greater in those who responded to the
DNA vaccine compared to those who did not (Figure 4).
IFN-c ELISPOT responses by antigen. Six weeks after
rAd5 alone there were no statistically significant differences
between the low and high dosage groups in the proportions of
volunteers responding to Pol, EnvA, EnvB or Gag. Similar results
were obtained, including responses to Nef, six weeks after the rAd5
boost (Table 5). There was one false positive response to Nef in a
Group B volunteer, who received a single dose of the rAd5
vaccine, which does not contain the Nef gene. Six weeks after
rAd5 alone, the most frequent responses were to Pol followed by
Env and then Gag, while 6 weeks after the rAd5 boost, the most
frequently observed responses were to Env, followed by Gag and
then Pol (Figure 5). The proportion of vaccine recipients with
IFN-c ELISPOT responses to at least 2 antigens was greater in
those receiving the high versus low dosage of rAd5 alone (54% vs.
23% respectively, for Groups B and A, p=0.226). After 3
Table 4. IFN-c ELISPOT Response Rates at Single Post Vaccination Time Points.
ELISPOT Responses
a
Group Dose Post Vaccination Time Point Low Dosage High Dosage Total
A and B rAd5 Alone Pre-Vaccination 0/13 0% (0%–25%) 1/12 8% (0%–38%) 1/25 4% (0%–20%)
6 Weeks 6/13 46% (19%–75%) 7/13 54% (25%–81%) 13/26 50% (30%–70%)
36 Weeks 4/13 31% (9%–61%) 4/12 33% (10%–65%) 8/25 32% (15%–54%)
48 Weeks 4/13 31% (9%–61%) 5/13 38% (14%–68%) 9/26 35% (17%–56%)
C and D 3DNA Prime Pre-Vaccination 0/29 0% (0%–12%) 1/28 4% (0%–18%) 1/57 2% (0%–9%)
4 Weeks 11/28 39% (22%–59%) 13/29 45% (26%–64%) 24/57 42% (29%–56%)
rAd5 Boost 6 Weeks
b 18/25 72% (51%–88%) 18/26 69% (48%–86%) 36/51 71% (56%–83%)
12 Weeks
b 18/27 67% (46%–83%) 18/27 67% (46%–83%) 36/54 67% (53%–79%)
24 Weeks
b 22/27 81% (62%–94%) 20/25 80% (59%–93%) 42/52 81% (67%–90%)
aFrequency (# Subjects) and percent (exact 95% confidence interval).
bTime interval given is post rAd5 boost.
doi:10.1371/journal.pone.0012873.t004
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responses to multiple antigens was 21% (Groups C and D
combined). After rAd5 boost, 62% and 66% of DNA primed
vaccinees in the LD and HD groups, respectively, had a positive
response (Figure 5). Comparing LD rAd5 alone with LD rAd5
boost, the response rates were 23% versus 62% (p=0.043), for HD
rAd5 alone versus HD rAd5 boost, the response rates, respectively,
were 54% and 66% (p=0.510).
DNA priming improved the proportion of vaccine recipients
with any positive response at more than one time point after the
rAd5 vaccination, with 31, 54, 69 and 64% in Groups A, B, C and
D, respectively. The difference was not statistically significant
(p=0.122 between all four groups, and p=0.054 for Groups A
and B versus Groups C and D, i.e., 42% versus 67%, respectively).
Figure S3 shows the frequency and distribution of peptide pool
responses over time in each group which provides an idea of the
breadth of the response to the vaccine regimens. Six pools are
included in the analysis; Gag, Nef, Env A and B and two Pol pools.
Responses of up to 4 pools were commonly observed across all the
groups and over multiple time points.
Ad5 neutralizing titers and relationship to IFN-c ELISPOT
responses. The distribution of baseline Ad5 titers is similar
across Groups A to D (p=0.332). There was no significant
difference in response rate to vaccination in any group of vaccine
recipients depending on baseline anti-Ad5 titers. (Figure S4). In
individuals with a baseline Ad5 titer .200, the response rate in
participants vaccinated with DNA prime - rAd5 boost was higher
(30/35; 86%) than in those receiving rAd5 alone (10/18; 56%:
p=0.0220). There was no effect of dosage. The numbers of
volunteers with baseline Ad5 neutralizing titer ,19 and 19–200
who responded were too small for comparisons. Four weeks after
administration of rAd5, the Ad5 antibody titer was significantly
increased in all groups. Titers in Group D were significantly higher
than in Group C (p=0.0056) (data not shown).
Intracellular cytokine staining (ICS). Samples from 13
vaccine and 5 placebo recipients from groups C and D were
assessed using an IL-2/IFN-c ICS assay at 2 weeks post DNA
prime and 4 weeks post Ad5 boost. The percent response rates for
ICS are shown in Table 6. CD4 T cell responses to Env, Gag and
Nef were detected after DNA prime and after Ad5 boost, but no
Pol specific responses were seen. CD8 T cell responses to Env, Nef
and Pol were detected after DNA prime - rAd5 boost, with fewer
responders seen after the DNA priming. One placebo recipient
had a false positive response to the EnvC pool. The magnitude of
cytokine secretion was modest; HIV-specific CD4 T cell responses
to any antigen were all ,0.3% and CD8 T-cell responses all
,0.32% except for one Pol response of 1.33%. Because of the
small numbers of samples per group, it was not possible to
determine whether there were differences in the frequencies and
magnitude of CD4 versus CD8 T cell responses.
Viral Inhibition Assay. A viral inhibition assay (VIA) has
previously been optimized and qualified using PBMC from HIV-
infected individuals with a range of viral loads (VL) and uninfected
low risk volunteers. To determine the criteria for assay positivity,
viral inhibition from 43 HIV–uninfected subjects was assessed. A
cut-off of .1.13 log10 viral inhibition was established based on a
Figure 3. Impact of DNA prime on ELISPOT responses. Comparison of percent ELISPOT responders after rAd5 alone (Groups A and B) versus
DNA prime - rAd5 boost over time (Groups C and D). Vertical lines represent 95% Confidence Intervals.
doi:10.1371/journal.pone.0012873.g003
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infected CD4 T cells with .99% confidence. With a qualified viral
inhibition assay, HIV seropositive individuals had a range of
responses with a trend toward higher viral inhibition in those with
lower viral loads. Treatment-naive HIV+ subjects with a plasma
VL of ,10 000/mL had median viral inhibition of 3.17 log10,
whereas those with VL .10000 had median viral inhibition of
1.12 log10 [21]. To assess how well the VIA works for vaccine
trials, seven samples from vaccinees who received DNA prime -
rAd5 boost and one sample from a placebo recipient were tested
and the results were recently published [21]. To extend these
findings, viral inhibition was assessed in seven individuals at 6
weeks and between 36–48 weeks after a single dose of rAd5 and in
a further 2 placebo individuals. The samples from vaccine
recipients were selected based on a range of positive ELISPOT
responses, from low (close to the cut-off) to high SFC counts, and
placebo samples were randomly selected. The laboratory
performing the assays remained blinded. Figure 6 shows data
from a total of 14 vaccine and 3 placebo recipients. All of the
participants with an available pre-vaccination specimen (2
placebos and 10 vaccinees) classified as negative (,1.13 log10)
for HIV-1IIIB inhibition. At 4 weeks post-3
rd DNA vaccination,
PBMC were available from 5 of the 7 vaccinees, and all were
negative for inhibition. Six and 12 weeks post rAd5 boost, CD8 T-
cells from all seven vaccinees efficiently inhibited HIV-1-IIIB
(median 2.22 and 1.48 log10). At 6 weeks post rAd5 alone, 6 of the
7 vaccinees efficiently inhibited HIV-1IIIB (median 2.87 log10).
Between 36–48 weeks post rAd5 alone, viral inhibition was still
present in 3 out of 6 vaccinees who had viral inhibition detected at
week 6, one sample was unavailable for testing. There was no
difference between VIA after Ad5 boost versus Ad5 alone at 6
weeks post-vaccination or any VIA post-Ad5 boost (n=14) versus
any post-Ad5 alone (n=13) (p=0.534 and p=0.792 respectively,
Wilcoxon test).
VIA activity was found in the presence of moderate to high Ad5
neutralization titers. At 4 weeks post rAd5, Ad5 neutralization titers
were available from 13 of the 14 vaccinees, 9 of the 13 individuals
had titers .8748 and 4 had titers .200 (1305–2667). No samples
were available from individuals with Ad5 titers of ,200.
HIV specific antibody responses. After rAd5 alone,
antibodies to EnvA, EnvB and EnvC were detected in,
respectively, 25%, 45% and 42% of volunteers in Group A and
in 50%, 58% and 58% of volunteers in Group B. After the rAd5
boost, the response to each Env protein was 89% in Group C and
100% in Group D. There was no effect of dosage. Antibodies to
Gag were detected after the LD and HD rAd5 boost in 25% and
31% of volunteers, respectively, compared to 8% and 0% after
rAd5 alone, whereas antibodies to pol and nef were detected
infrequently in all groups (data not shown). None of the placebo
group had antibody responses to the HIV antigens. Antibody
ELISA titers are shown in Figure 7 post rAd5 for each of groups
A–D. Comparison of ELISA titers between the 4 study groups was
made separately within each of the 4 peptides Env A, Env B, Env
C and Gag using the non-parametric Wilcoxon 2-sample test.
Allowing for multiple comparisons, a p-value of less than 0.025 is
required for an overall significance level. For Env A, B and C, the
Figure 4. Impact of DNA prime on ELISPOT magnitude. Values plotted are the mean background-subtracted ELISPOT counts (Spot Forming
Cells, SFC) over all positive peptide responses per volunteer at that visit. Shaded bars are subjects with any positive response at 4 weeks post 3
rd DNA,
white boxes are those with no positive responses at this time point.
doi:10.1371/journal.pone.0012873.g004
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(p,.0001) than in groups A and B. There were no statistically
significant differences between Gag titers. The median antibody
ELISA titers after DNA alone were ,30 and below the cut-off of
the assay (data not shown).
HIV neutralizing activity. Only 2 individuals in Group D
had moderate neutralizing activity against SF162 and no
detectable neutralizing activity against 12 other HIV-1 isolates
(data not shown). Similar HIV-1 binding ELISA and HIV
neutralization activity was seen in individuals in a recently
Table 5. Percent of Volunteers with Positive IFN-c ELISPOT Response to Vaccine Antigens.
Group Env A Env B Gag Nef Pol Any
A 6 Weeks Post rAd5 Alone 23.1 23.1 7.7 0.0 38.5 46.2
B 6 Weeks Post rAd5 Alone 30.8 30.8 15.4 7.7 46.2 53.8
C 4 Weeks Post 3DNA 25.0 22.2 17.9 18.5 3.6 39.3
6 Weeks Post rAd5 Boost 64.0 54.2 40.0 8.3 20.0 72.0
D 4 Weeks Post 3DNA 20.7 24.1 31.0 7.4 0.0 44.8
6 Weeks Post rAd5 Boost 50.0 42.3 42.3 11.5 26.9 69.2
Total 4 Weeks Post 3DNA 22.8 23.2 24.6 13.0 1.8 42.1
6 Weeks Post rAd5 Alone 26.9 26.9 11.5 3.8 42.3 50.0
6 Weeks Post rAd5 Boost 56.9 48.0 41.2 10.0 23.5 70.6
doi:10.1371/journal.pone.0012873.t005
Figure 5. Magnitude of ELISPOT and % response rate. The magnitude of the response was measured by SFC per million peripheral blood
mononuclear cells (SFC/m PBMC). The x-axis row one shows the peptide pool, row two the % response rate and row three the vaccine group. Black
dots indicate positive responses, defined by background-subtracted values greater than the cutoff, more than 3 times mean background SFC count,
and a coefficient of variation of not more than 70% amongst replicate wells. The rAd5 response rates correspond to both dose groups combined. The
box plots summarize positive responses only (i.e., median, 1
st and 3
rd quartiles, minimum/maximum). The cut-offs for EnvA, EnvB, Gag, Nef, PolB1 and
PolB2, as determined by the level of non-specific responses from at least 180 samples from unvaccinated individuals, are 40, 51, 54, 68, 51 and 38
respectively. The Pol response is the maximum of PolB1 and PolB2 and positive if either one is positive.
doi:10.1371/journal.pone.0012873.g005
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samples showed neutralizing activity above cut-off.
HIV serology at the end of study. Twelve months after
rAd5 alone and 6 months after the rAd5 boost, 10/13 (76%) and
48/57 (84%) vaccine recipients, respectively, had a positive HIV
test result by at least one commercial HIV ELISA kit without
being HIV-infected. Four months after 3 DNA injections and
immediately prior to the rAd5 boost, only 6/57 (10%) vaccine
recipients had a positive HIV test result. The Detect HIV v2 kit
did not detect vaccine-induced antibodies in any vaccine recipient.
2/30 (7%) placebo recipients had a false positive HIV test result.
Discussion
In this study, the VRC HIV-1 rAd5 vaccine was generally well-
tolerated when given alone or as boost following the VRC HIV-1
DNA vaccine to healthy, HIV-seronegative African adults at low
risk for HIV infection. The reactogenicity seen in this study was
consistent with earlier phase I studies evaluating these products
[2,3,4,5].
The DNA prime - rAd5 boost vaccination schedule was highly
immunogenic even in volunteers with neutralizing antibodies
against Ad5 at baseline. IFN-c ELISPOT responses were most
frequent to Env and Gag epitopes and were maintained at least 6
months after the rAd5 boost. Overall, there was no dosage effect
on the frequency of IFN-c ELISPOT responses at 6 weeks after
rAd5 alone or rAd5 boost.
Compared to rAd5 alone, DNA priming increased the
frequency of IFN-c ELISPOT response after the rAd5 boost,
but the difference was not statistically significant 6 weeks after
rAd5 administration. DNA priming also increased the magnitude
and the durability of the T-cell responses and resulted in
immunodominance of Env and Gag over Pol consistent with the
results from the RV 172 study [8]. In our study, responses to Pol
were highest after rAd5 alone. Contrary to our findings, responses
to Env in RV 172 were not different between rAd5 alone and
DNA prime – rAd5 boost groups [8]. These findings may be
relevant for future antigen design of T cell based vaccines.
Vaccine-specific antibodies were detected to EnvA, EnvB and
EnvC, and to Gag after DNA prime and rAd5 alone; after DNA
prime - rAd5 boost, significantly higher magnitude of antibody
titers and frequency of responders were detected. However, there
Table 6. ICS Responses Post DNA Prime - rAd5 Boost.
Number of responders/total tested (% responders)
Baseline 2 weeks post 3DNA 4 weeks post rAd5
Peptide Pool V02 Placebo 3DNA Placebo Low Dosage High Dosage
CD4
Any Env 0/13 (0.0%) 1/5 (20.0%) 8/13 (61.5%) 0/5 (0.0%) 3/6 (50.0%) 5/7 (71.4%)
Env A 0/13 (0.0%) 0/5 (0.0%) 6/13 (46.2%) 0/5 (0.0%) 3/6 (50.0%) 4/7 (57.1%)
Env B 0/13 (0.0%) 0/5 (0.0%) 4/13 (30.8%) 0/5 (0.0%) 1/6 (16.7%) 1/7 (14.3%)
Env C 0/13 (0.0%) 1/5 (20.0%) 7/13 (53.8%) 0/5 (0.0%) 1/6 (16.7%) 5/7 (71.4%)
Gag B 0/13 (0.0%) 0/5 (0.0%) 8/13 (61.5%) 0/5 (0.0%) 2/6 (33.3%) 2/7 (28.6%)
*Nef B 0/11 (0.0%) 0/5 (0.0%) 2/11 (18.2%) 0/5 (0.0%) 1/6 (16.7%) 0/5 (0.0%)
Any Pol 0/13 (0.0%) 0/5 (0.0%) 0/13 (0.0%) 0/5 (0.0%) 0/6 (0.0%) 0/7 (0.0%)
CD8
Any Env 0/13 (0.0%) 0/5 (0.0%) 3/13 (23.1%) 0/5 (0.0%) 4/6 (66.7%) 3/7 (42.9%)
Env A 0/13 (0.0%) 0/5 (0.0%) 2/13 (15.4%) 0/5 (0.0%) 4/6 (66.7%) 3/7 (42.9%)
Env B 0/13 (0.0%) 0/5 (0.0%) 3/13 (23.1%) 0/5 (0.0%) 2/6 (33.3%) 3/7 (42.9%)
Env C 0/13 (0.0%) 0/5 (0.0%) 0/13 (0.0%) 0/5 (0.0%) 0/6 (0.0%) 0/7 (0.0%)
Gag B 0/13 (0.0%) 0/5 (0.0%) 0/13 (0.0%) 0/5 (0.0%) 0/6 (0.0%) 1/7 (14.3%)
*Nef B 0/13 (0.0%) 0/5 (0.0%) 2/13 (15.4%) 0/5 (0.0%) 1/6 (16.7%) 0/7 (0.0%)
Any Pol 0/13 (0.0%) 0/5 (0.0%) 1/13 (7.7%) 0/5 (0.0%) 1/6 (16.7%) 3/7 (42.9%)
*Two volunteers had CD4 responses to Nef at all 3 visits. These Nef responses have been excluded.
doi:10.1371/journal.pone.0012873.t006
Figure 6. Induction of CD8 T cell-mediated inhibition of HIV-1-
IIIB replication following vaccination with a DNA prime - rAd5
boost or rAd5 alone regimen. Viral inhibition was assessed in
placebo recipients and prior to any vaccination (N); following DNA
alone (&); DNA prime - rAd5 boost at 6 and 12 weeks (mand
nrespectively) and after rAd5 alone at 6 and between 36 to 48 weeks
(¤ and e respectively). The 1.13 log10 inhibition value above which
inhibition is considered HIV-1 specific is indicated by the hashed line.
Medians for all groups are indicated (— —).
doi:10.1371/journal.pone.0012873.g006
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comparing Groups A and B and Groups C and D.
This study and others suggest that DNA priming may alter the
impact of pre-existing Ad5 immunity on vaccine-induced immune
responses and alter the quality and/or quantity of elicited T cell
and antibody responses [22,6].
A limited evaluation of ICS responses indicated that both CD4
and CD8 responses were elicited. Other studies have shown a
predominant CD4 response after DNA alone, predominant CD8
response after rAd5 alone and a balanced response after DNA
prime - rAd5 boost [3,5,6,22].
Although it remains to be seen whether VIA activity is a true
correlate of HIV protection, VIA activity has been shown to be
associated with control of HIV [21,23,24]. Treatment-naive HIV+
subjects with a plasma viral load of ,10 000/mL had median viral
inhibition of 3.17 log10, whereas those with viral load .10000 had
median viral inhibition of 1.12 log10 [21]. In this study, CD8 T
cells from individuals vaccinated with DNA prime - rAd5 boost or
rAd5 alone had a range of inhibition up to 3.7 log10 units. The
difference in VIA activity between rAd5 alone and DNA prime -
rAd5 boost was not statistically significant.
At the end of the study, most vaccine recipients tested positive
on at least one commercial HIV antibody kit without being HIV-
infected. Use of a commercial kit that is least likely to register
vaccine-induced antibody as positive is advisable; a purpose-built
kit such as HIV-SELECTEST, if eventually approved, may
facilitate diagnostic HIV testing in vaccine recipients [25] within
the study. In an observational follow up study of V001 volunteers,
rapid HIV tests that incorporate only HIV-1 envelope proteins did
not consistently detect vaccine-induced antibodies [26]. Therefore,
cautious use of rapid HIV tests may be possible for long term
follow up of HIV vaccine recipients, but volunteers must be
warned that they may test falsely HIV positive for some time.
Specialized testing services will be provided by these clinical sites
until the false positive tests fade.
In Africa, the prevalence of pre-existing antibodies from natural
exposure to adenovirus type 5 is at least 80% (IAVI unpublished
data) compared to 30–60% in the US [27,28]. This may be of
concern: vaccine take may be compromised, leading to attenua-
tion of immune responses to the rAd5 vector. In our study, the
overall frequency of HIV-specific immune responses to the rAd5
vaccine was somewhat lower than reported in US volunteers,
perhaps because of the higher Ad5 seroprevalence seen in the
majority of our study participants [2], but there may be other
reasons responsible for the differences observed, e.g., race,
geographical area, population characteristics, nutritional status.
Our findings are also consistent with the findings from the Merck
Phase IIb (STEP) study, where pre-existing immunity reduced the
immunogenicity of the MRK rAd5 gag-pol-nef vaccine [9].
However, it is important to note, that there are differences in
properties and vaccination regimens between the VRC and the
MRK vaccines and that results from the V001 and STEP study
may not be comparable. With respect to the increased HIV
incidence in uncircumcised male vaccinees with pre-existing
immunity to Ad5 in the STEP study, a recent publication suggests
that pre-existing serological immunity to Ad5 in itself does not
appear to be associated with increased risk of HIV acquisition
[29]. Uncircumcised status in males was a stronger predictor of
HIV acquisition than pre-existing immunity to Ad5.
The V001 study was completed before the results from the
STEP study (HVTN 502) became available; therefore, those
results did not influence the conduct of the study [9,10]. However,
all former V001 participants were informed about the STEP study
results, as were all IRBs/IECs and national regulatory agencies.
Currently, a focused Phase II study is evaluating the VRC HIV-
1 DNA prime - rAd5 boost combination for its effect on early
control of viral load in those study participants who become HIV-
1 infected. The study is enrolling Ad5 seronegative and
circumcised men who have sex with men in the USA (HVTN
505; http://clinicaltrials.gov/ct2/show/NCT00865566).
Figure 7. HIV antibody titers. Distribution of HIV-specific antibody titers at 1 month post rAd5 alone (Groups A and B) and rAd5 boost (Groups C
and D) in vaccine recipients, by protein and treatment group. The Y-axis shows the antibody titer on a log scale with box plots showing the median,
1
st and 3
rd quartiles.
doi:10.1371/journal.pone.0012873.g007
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as rAd35 and rAd26, are also in early clinical trials as prophylactic
vaccines for HIV and other diseases. The advantage of these
vectors may be a lower seroprevalence [28,30] in humans
compared to Ad5. The effect of pre-existing immunity to these
vectors on the immunogenicity of rAd vectored vaccines remains
to be seen.
In addition, enormous efforts are being made to develop HIV
vaccines capable of inducing neutralizing HIV antibodies and to
design replicating viral vectors. While basic discovery and applied
research are crucial for the development of a safe and efficacious
HIV vaccine, it is important to continue to perform focused human
clinical trials of different vaccine strategies to develop a highly
effective and safe preventive HIV vaccine [31]. New functional T
cell assays that allow determination of correlates of protection and/
or predict vaccine efficacy are also urgently needed.
Supporting Information
Figure S1 Local reactogenicity by Ad5 baseline titers. Ad5
neutralizing titers were stratified by values obtained prior to
vaccination; ,19, 19–200 and .200 as measured by the Crucell
luciferase-based assay. N=numbers of individuals in each group.
Found at: doi:10.1371/journal.pone.0012873.s001 (0.33 MB TIF)
Figure S2 Systemic reactogenicity by Ad5 baseline titers. Ad5
neutralizing titers were stratified by values obtained prior to
vaccination; ,19, 19–200 and .200 as measured by the Crucell
luciferase-based assay. N=numbers of individuals in each group.
Found at: doi:10.1371/journal.pone.0012873.s002 (0.22 MB TIF)
Figure S3 Percent of volunteers responding to HIV-peptide
pools. The table shows the number of subjects per group at each
time point that contributed ELISPOT data for the bar graph. Six
pools are included in the analysis; Gag, Nef, Env A, Env B and two
Pol pools. The numbers inside the bars represent percent of the
responder frequencies.
Found at: doi:10.1371/journal.pone.0012873.s003 (0.31 MB TIF)
Figure S4 Impact of Ad5 neutralizing antibody on IFN-c
ELISPOT responses. The bars show the cumulative proportion of
vaccine recipients with positive ELISPOT responses in those with
a baseline Ad5 titer .200 after the rAd5 boost in groups A–D.
The p-values shown on the X-axis are based on Fisher’s exact 2-
tailed test.
Found at: doi:10.1371/journal.pone.0012873.s004 (0.21 MB TIF)
Protocol S1 A Phase I Randomized, Placebo-Controlled,
Double-Blind Trial to Evaluate the Safety and Immunogenicity
of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by
Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or
the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in
Healthy Adult Volunteers not Infected with HIV
Found at: doi:10.1371/journal.pone.0012873.s005 (5.64 MB
PDF)
CONSORT Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0012873.s006 (0.22 MB
DOC)
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